Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Care

Febbo, Phillip G.; Allo, Mina; Alme, Emma B.; Cuyun Carter, Gebra; Dumanois, Robert; Essig, Alessia; Kiernan, Estevan; Kubler, Caitlin B.; Martin, Nikki; Popescu, Medeea C.; Leiman, Lauren C.

doi:10.1200/po.23.00382

Cited by 9 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinician education is critical to the implementation of any new technology into clinical practice, however implementation of liquid biopsy in the primary care setting is further complicated by the number of primary care physicians and their high workload/wide breadth of practice ( 200 , 204 ). As outlined, liquid biopsy for early cancer detection is an emerging field with different technologies becoming available.…”

Section: Accessing Liquid Biopsy For Women In the Postpartum Periodmentioning

confidence: 99%

Status of breast cancer detection in young women and potential of liquid biopsy

Stibbards-Lyle,

Malinovska,

Badawy

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Young onset breast cancer (YOBC) is an increasing demographic with unique biology, limited screening, and poor outcomes. Further, women with postpartum breast cancers (PPBCs), cancers occurring up to 10 years after childbirth, have worse outcomes than other young breast cancer patients matched for tumor stage and subtype. Early-stage detection of YOBC is critical for improving outcomes. However, most young women (under 45) do not meet current age guidelines for routine mammographic screening and are thus an underserved population. Other challenges to early detection in this population include reduced performance of standard of care mammography and reduced awareness. Women often face significant barriers in accessing health care during the postpartum period and disadvantaged communities face compounding barriers due to systemic health care inequities. Blood tests and liquid biopsies targeting early detection may provide an attractive option to help address these challenges. Test development in this area includes understanding of the unique biology involved in YOBC and in particular PPBCs that tend to be more aggressive and deadly. In this review, we will present the status of breast cancer screening and detection in young women, provide a summary of some unique biological features of YOBC, and discuss the potential for blood tests and liquid biopsy platforms to address current shortcomings in timely, equitable detection.

show abstract

Section: Accessing Liquid Biopsy For Women In the Postpartum Periodmentioning

confidence: 99%

Status of breast cancer detection in young women and potential of liquid biopsy

Stibbards-Lyle,

Malinovska,

Badawy

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Prospective multi-center ctDNA-adapted clinical trials including a wider breadth of B-NHL subtypes are needed to realize the potential of ctDNA in clinical practice. It is worthwhile to highlight that even once ctDNA is approved for clinical use in B-NHL, affordability and accessibility of testing will remain major concerns that may limit widespread adoption [87].…”

Section: Barriers In Bringing Ctdna From Bench To Bedsidementioning

confidence: 99%

Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas

Monick,

Rosenthal

2024

Cancers

View full text Add to dashboard Cite

The emergence of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment paradigm for R/R B-cell NHLs. However, challenges persist in accurately evaluating treatment response and detecting early relapse, necessitating the exploration of novel biomarkers. Circulating tumor DNA (ctDNA) via liquid biopsy is a non-invasive tool for monitoring therapy efficacy and predicting treatment outcomes in B-NHL following CAR-T therapy. By overcoming the limitations of conventional imaging modalities, ctDNA assessments offer valuable insights into response dynamics, molecular mechanisms of resistance, and early detection of molecular relapse. Integration of ctDNA monitoring into clinical practice holds promise for personalized therapeutic strategies, guiding the development of novel targeted therapies, and enhancing patient outcomes. However, standardization of assay methodologies and consensus on clinical response metrics are imperative to unlock the full potential of ctDNA in the management of B-NHL. Prospective validation of ctDNA in clinical trials is necessary to establish its role as a complementary decision aid.

show abstract

“…In the article that accompanies this editorial by Febbo et al, 1 the authors (industry leaders and members of the nonprofit BLOODPAC Consortium) list six major barriers to liquid biopsy implementation at the population level: uncertainty around assay performance, unfamiliarity with the assay and its indications, issues with payer coverage, health care-level discrimination, mistrust, and confusion over language. The authors then discuss broad-based responses to address these barriers and highlight the importance of involving the key stakeholders including clinicians, payers, regulators, policy makers, and patient groups.…”

mentioning

confidence: 99%